IPILIMUMAB, NIVOLUMAB, PAZOPANIB clinical trials

RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype

This study compares two treatments for rare advanced sarcomas: a combination of nivolumab and ipilimumab, or pazopanib alone. It aims to see which treatment best stops the cancer from growing or spreading and helps people live longer.